These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 9310577)

  • 1. Impact of postmenopausal hormone therapy on cardiovascular events and cancer. Paper's main conclusion is no longer justified when data from all trials are considered.
    Seagroatt V
    BMJ; 1997 Sep; 315(7109):677; author reply 678-9. PubMed ID: 9310577
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of postmenopausal hormone therapy on cardiovascular events and cancer. Study's conclusions were incorrect.
    Col NF; Wong JB; Pauker SG; Karas R
    BMJ; 1997 Sep; 315(7109):678; author reply 678-9. PubMed ID: 9310580
    [No Abstract]   [Full Text] [Related]  

  • 3. Impact of postmenopausal hormone therapy on cardiovascular events and cancer. Combining thromboembolic events with cardiovascular events does not support odds ratio of 0.7.
    Sundkvist T
    BMJ; 1997 Sep; 315(7109):677. PubMed ID: 9310578
    [No Abstract]   [Full Text] [Related]  

  • 4. Impact of postmenopausal hormone therapy on cardiovascular events and cancer. Inclusion of one particular study was inappropriate.
    al-Azzawi F; Thompson J; Halligan A
    BMJ; 1997 Sep; 315(7109):677-8. PubMed ID: 9310579
    [No Abstract]   [Full Text] [Related]  

  • 5. Impact of postmenopausal hormone therapy on cardiovascular events and cancer. More women are excluded from treatment arm of such trials because of cardiovascular events.
    Singleton S; Bailey K
    BMJ; 1997 Sep; 315(7109):676. PubMed ID: 9310575
    [No Abstract]   [Full Text] [Related]  

  • 6. Postmenopausal hormone therapy and the risk of cardiovascular disease.
    Bittner V
    Expert Opin Pharmacother; 2009 Sep; 10(13):2041-53. PubMed ID: 19563274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative cardiovascular effects of different progestins in menopause.
    Rosano GM; Fini M
    Int J Fertil Womens Med; 2001; 46(5):248-56. PubMed ID: 11720197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postmenopausal hormone therapy: cardiovascular risks.
    Prescrire Int; 2003 Apr; 12(64):65-9. PubMed ID: 12674130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Meta-analysis finds cardioprotective effects: renaissance of hormone replacement therapy? Interview by Katharina Arnheim].
    Kuhl H
    MMW Fortschr Med; 2006 Jun; 148(26):14. PubMed ID: 16878361
    [No Abstract]   [Full Text] [Related]  

  • 10. Estrogen replacement therapy (ERT) and hormone replacement therapy (HRT) in the prevention of cardiovascular diseases.
    Nikolov R; Golbs S; Schneider HP
    Zentralbl Gynakol; 1999; 121(2):101-4. PubMed ID: 10096179
    [No Abstract]   [Full Text] [Related]  

  • 11. The controversy over estrogen replacement therapy: an update on clinical trials.
    Gnatuk CL
    Curr Womens Health Rep; 2002 Apr; 2(2):89-94. PubMed ID: 12116607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time for new long-term trials of postmenopausal hormone therapies!
    MacLennan A; Sturdee DW
    Climacteric; 2003 Dec; 6(4):265-7. PubMed ID: 15006246
    [No Abstract]   [Full Text] [Related]  

  • 13. [Postmenopausal hormone replacement therapy and cardiovascular disease].
    Høibraaten E
    Tidsskr Nor Laegeforen; 2002 Jun; 122(16):1564-5. PubMed ID: 12119783
    [No Abstract]   [Full Text] [Related]  

  • 14. [The story of the reversal of opinion about hormone replacement therapy and cardiovascular disease].
    Løkkegaard EC
    Ugeskr Laeger; 2005 Mar; 167(10):1166-70. PubMed ID: 15810574
    [No Abstract]   [Full Text] [Related]  

  • 15. Preserving cardiovascular benefits of hormone replacement therapy.
    Bush TL
    J Reprod Med; 2000 Mar; 45(3 Suppl):259-73. PubMed ID: 10756507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of postmenopausal hormone therapy on cardiovascular events and cancer. Search for studies was limited.
    Shah S; Rhodes L
    BMJ; 1997 Sep; 315(7109):676-7; author reply 678-9. PubMed ID: 9310576
    [No Abstract]   [Full Text] [Related]  

  • 17. [Hormonal replacement therapy and selective estrogen receptor modulators in prevention of cardiovascular disease].
    Kozakiewicz K; Wycisk A
    Wiad Lek; 2006; 59(5-6):377-82. PubMed ID: 17017486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormone therapy and cardiovascular disease--still much to be learnt.
    Mikkola TS; Ylikorkala O
    Gynecol Endocrinol; 2005 Feb; 20(2):116-20. PubMed ID: 15823832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of SERM on breast cancer and cardiovascular disease: making a comparison between raloxifene use and hormone replacement therapy on the risks of the diseases].
    Higuchi T; Mizunuma H
    Clin Calcium; 2004 Oct; 14(10):81-4. PubMed ID: 15577136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postmenopausal hormone replacement therapy and prevention: no chance for celebration? What should doctors do? A personal opinion.
    Rossi R; Modena MG
    Ital Heart J; 2002 Dec; 3(12):693-8. PubMed ID: 12611118
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.